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We investigated the angiotensin II (Ang II)-generating system by
analyzing the vasoconstrictor effect of Ang II, angiotensin I (Ang I),
and tetradecapeptide (TDP) renin substrate in the absence and pres-
ence of inhibitors of the renin-angiotensin system in isolated rat aortic
rings and mesenteric arterial beds with and without functional endo-
thelium. Ang II, Ang I, and TDP elicited a dose-dependent vasocon-
strictor effect in both vascular preparations that was completely
blocked by the Ang II receptor antagonist saralasin (50 nM). The
angiotensin converting enzyme (ACE) inhibitor captopril (36 µM)
completely inhibited the vasoconstrictor effect elicited by Ang I and
TDP in aortic rings without affecting that of Ang II. In contrast,
captopril (36 µM) significantly reduced (80-90%) the response to
bolus injection of Ang I, without affecting those to Ang II and TDP in
mesenteric arteries. Mechanical removal of the endothelium greatly
potentiated (70-95%) the vasoconstrictor response to Ang II, Ang I,
and TDP in aortic rings while these responses were unaffected by the
removal of the endothelium of mesenteric arteries with sodium deoxy-
cholate infusion. In addition, endothelium disruption did not change
the pattern of response elicited by these peptides in the presence of
captopril. These findings indicate that the endothelium may not be
essential for Ang II formation in rat mesenteric arteries and aorta, but
it may modulate the response to Ang II. Although Ang II formation
from Ang I is essentially dependent on ACE in both vessels, our results
suggest the existence of an alternative pathway in the mesenteric
arterial bed that may play an important role in Ang II generation from
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There is substantial evidence for the pres-
ence of essential components of the renin-
angiotensin system (renin, angiotensinogen,
angiotensin converting enzyme (ACE), an-
giotensin peptides and angiotensin recep-
tors) in a variety of tissues, including blood
vessels and heart, suggesting the existence of
a local renin-angiotensin system (1). How-
ever, several studies using ACE inhibitors
have raised questions as to whether ACE is
the sole enzyme responsible for angiotensin
II (Ang II) formation in vivo, since this pep-
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tide is detected in plasma (2) and tissues (3)
despite ACE inhibition. In addition, the ex-
istence of alternative Ang II-forming path-
ways in the rat vasculature (4-6) and human
heart (7) has been reported.
Vascular endothelium participates ac-
tively in the control of vascular tone through
the synthesis and metabolism of a number of
vasoactive substances. In particular, vascu-
lar endothelium has been shown to be a
major site of conversion of circulating an-
giotensin I (Ang I) to Ang II by ACE located
on its luminal surface (8). Also, cultured
bovine aortic endothelial cells have been
shown to contain renin and angiotensinogen
and to be capable of synthesizing and secret-
ing angiotensins (9). Thus, endothelial cells
seem to play an important role in the vascu-
lar formation of Ang II. However, in phar-
macological studies in which large vessels
were used, such as rabbit aorta, rat aorta, and
rat femoral and caudal arteries, conversion
of Ang I to Ang II occurred in the absence of
the endothelial layer (10-13). Such appar-
ently contradictory data may be due to the
use of a variety of protocols applied to dif-
ferent studies or due to the diverse character-
istics of distinct vessels from the same or
from different animal species.
Given the above controversial data, we
investigated the role of the endothelium in
generating Ang II from Ang I and tetrade-
capeptide (TDP) renin substrate in both large
and resistance vessels. The vasoconstrictor
effect of Ang II, Ang I, and TDP on isolated
rat mesenteric arteries and aortic rings with
and without functional endothelium was an-
alyzed in the presence and absence of an
ACE inhibitor and Ang II receptor antago-
nist.
Material and Methods
Experiments were performed using 15-
20-week old male Wistar rats (250-300 g)
with free access to standard rat chow and tap
water.
Perfused mesenteric arterial bed
The rats were anesthetized with ethyl
ether and, after opening the abdominal cav-
ity, the superior mesenteric artery was per-
fused through a polyethylene cannula (PE-
50; Clay-Adams, Parsippany, NJ) inserted
into the artery at its origin from the aorta
with 10 ml of a modified Krebs solution
(120.0 mM NaCl, 4.7 mM KCl, 3.0 mM
CaCl2, 1.43 mM MgCl2, 25.0 mM NaHCO3,
1.17 mM KH2PO4, 11.0 mM glucose and
0.03 mM EDTA) containing 500 IU heparin.
The intestine was severed from the mesen-
tery by cutting close to the intestinal border
and the mesentery was removed from the rat
and placed ready for perfusion in a water
jacketed organ bath maintained at 37oC. The
mesenteric arteries were perfused with Krebs
olution equilibrated with 95% O2 and 5%
CO2, pH 7.4, at a constant rate of 4 ml/min,
using a peristaltic pump (LKB-2115 multi-
perpex pump, Bromma, Sweden). Perfusion
pressure was recorded via a side arm of the
mesenteric artery perfusion cannula with an
HP-1280C pressure transducer and an HP-
7754B recorder (Hewlett-Packard, Palo Alto,
CA). After a 30-min stabilization period,
phenylephrine was added to the perfusion
solution at increasing concentrations (3 to 6
µM) until a stable perfusion pressure (100-
120 mmHg) was achieved, in order to avoid
Ang II tachyphylaxis (6).
Endothelium was disrupted by infusing
sodium deoxycholate (1.0 mg/ml in saline)
for 60 s at a perfusion rate of 4 ml/min (14).
The successful disruption of the endotheli-
um was confirmed in each preparation by the
failure of acetylcholine (Ach; 11 pmol, bo-
lus injection) to elicit relaxation in the mes-
enteric arteries precontracted with phenyl-
ephrine. This procedure did not affect the
ability of the vascular smooth muscle of the
mesenteric arteries to respond to sodium
nitroprusside (67 pmol), which induces en-
dothelium-independent vasodilatation.
Dose-response curves for Ang II (2.4-
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38.4 pmol), Ang I (19.3-308.8 pmol), and
TDP (142.1-2273.6 pmol) were obtained by
bolus injection of 10-40 µl of the peptide
solution (diluted in Krebs) into the perfusion
stream before the pump. Injection of 40 µl of
Krebs solution did not affect basal perfusion
pressure. Single responses to Ang II (19
pmol), Ang I (116 pmol), and TDP (568
pmol) that produced an increase in perfusion
pressure of approximately 40 mmHg, corre-
sponding to 60% of the maximal response,
were determined in the same preparation
before and after: a) addition of the Ang II
receptor antagonist [Sar1-Ile5-Ala8]Ang II
(saralasin; 50 nM), b) addition of the ACE
inhibitor captopril (36 µM), c) perfusion of
sodium deoxycholate (1 mg/ml during 60 s),
and d) perfusion of sodium deoxycholate in
the presence of captopril (36 µM). The inter-
val between the injections was at least 15
min to avoid tachyphylactic responses.
Saralasin and captopril were added to the
perfusion solution and allowed to act for 30
min before testing the pressor response in-
duced by the agonists.
Isolated aortic rings
The rats were killed by decapitation, and
the thoracic aorta was removed and placed
in an ice-cold oxygenated modified Krebs
solution containing 135.0 mM NaCl, 5.0
mM KCl, 2.5 mM CaCl2, 1.4 mM MgSO4,
20.0 mM NaHCO3, 1.17 mM KH2PO4, 11.0
mM glucose and 0.03 mM EDTA. The aorta
was then carefully cleaned of adhering con-
nective tissue and cut into rings (2-3 mm
wide). The rings were suspended with two
L-shaped stainless steel hooks under an ini-
tial tension of 1.0 g in a 10-ml jacketed tissue
bath filled with a modified Krebs solution at
37oC gassed with 95% O2 and 5% CO2, pH
7.4. Contractile responses were measured
with an isometric strain-gauge (UTC3, Gould-
Statham, Cleveland, OH) coupled to a re-
cording system (R-611, Beckman Inst. Inc.,
Schiller Park, IL). After a 30-min equilibra-
tion period with buffer replaced every 10
min, the rings were contracted with phenyl-
ephrine (50 nM) and treated with acetylcho-
line (28 nM) to confirm the integrity of the
endothelium.
Endothelium was removed by gently
scraping the endothelial cells away from the
intima. The successful destruction of endo-
thelial function was confirmed by the failure
of acetylcholine (28 nM) to elicit relaxation
in aortic rings half maximally precontracted
with phenylephrine (50 nM). This procedure
did not affect the relaxation induced by so-
dium nitroprusside (45 nM).
Dose-response curves for Ang II (2.4-
19.0 nM), Ang I (2.0-16.0 nM), and TDP
(7.0-114.0 nM) were obtained by adding the
appropriate concentration to the bath. Each
preparation received four or five different
doses of just one of these peptides. Single
responses to Ang II (5 nM), Ang I (5 nM),
and TDP (19 nM) that produced an increase
in tension of approximately 250 mg, corre-
sponding to 75% of the maximal response,
were determined in the same preparation
before and after: a) addition of the Ang II
receptor antagonist [Sar1-Ile8]Ang II (50 nM),
b) addition of captopril (36 µM), c) mechan-
ical disruption of the endothelium, and d)
mechanical disruption of the endothelium in
the presence of captopril (36 µM). The inter-
val between the addition of the peptides was
20 min, with the buffer replaced every 5 min
to avoid tachyphylaxis. [Sar1-Ile8]Ang II and
captopril were added to the organ bath and
allowed to act for 20 min before testing the
contractile effect of the agonists.
Drugs and reagents
Captopril was obtained from Squibb
(Princeton, NJ). Phenylephrine, sodium
deoxycholate, Ach, sodium nitroprusside,
[Sar1-Ile8]Ang II, saralasin, Ang I, Ang II
and TDP (porcine) were purchased from
Sigma Chemical Co. (St. Louis, MO). The
concentration of each peptide stock solution
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Results
Perfused mesenteric arterial bed
Ang II, Ang I and TDP produced a dose-
dependent increase in perfusion pressure of
the mesenteric vascular bed (intact prepara-
tions), with a similar maximal pressor re-
sponse, as shown in Figure 1. When com-
pared on an equipressor basis, from data
presented in this figure (35 mmHg; 50% of
the maximum response), Ang I and TDP had
about 12.0% and 1.6%, respectively, of the
pressor activity of Ang II on isolated mesen-
teric arteries.
The vasoconstrictor responses elicited by
bolus injections of Ang II, Ang I and TDP
were completely abolished by saralasin (50
nM) in the perfusion fluid. In the presence of
captopril (36 µM), the pressor response elic-
ited by Ang I was significantly reduced,
whereas the responses to both Ang II and
TDP were unaffected (Figure 2). Addition of
saralasin or captopril to the perfusion solu-
tion did not affect basal perfusion pressure.
In intact preparations, Ach (11 pmol)
caused a drop in perfusion pressure of the
mesenteric arteries preconstricted with phen-
ylephrine, indicating the presence of func-
tional endothelium. After deoxycholate per-
fusion, the Ach response was abolished,
whereas the pressor responses elicited by
Ang II, Ang I, and TDP remained basically
unchanged (Figure 3, upper panel). The pres-
sor response caused by Ang I in the absence
of functional endothelium, as indicated by
the lack of response to Ach, was significant-
ly reduced by captopril, while that caused by
TDP was not significantly affected by the
addition of the ACE inhibitor (Figure 3,
lower panel).
Aortic rings
In intact preparations of aortic rings, Ang
II, Ang I and TDP produced a dose-depend-
ent increase in tension with a similar maxi-
Figure 1 - Changes in perfusion
pressure in the isolated rat mes-
enteric arterial bed induced by
bolus injections of angiotensin II
(Ang II; N = 7), angiotensin I (Ang
I; N = 9), and tetradecapeptide
(TDP; N = 7) renin substrate.































Figure 2 - Changes in perfusion
pressure in the isolated rat mes-
enteric arterial bed induced by
bolus injections of angiotensin II
(Ang II; 19 pmol), angiotensin I
(Ang l; 116 pmol), and tetrade-
capeptide (TDP; 568 pmol) renin
substrate during a control period
and in the presence of 50 nM
saralasin or 36 µM captopril in
the perfusion solution. Data are
reported as mean ± SEM and
correspond to 12, 4 and 8 obser-
vations for the control period,
saralasin and captopril, respec-
tively. *P<0.001 compared to
































(1.0 mg/ml) was determined by amino acid
analysis. The analysis of Ang I and TDP
samples by reverse-phase high-pressure liq-
uid chromatography revealed no contamina-
tion with Ang II.
Statistical analysis
Results are reported as the mean ± SEM.
Statistical analysis was performed by the
paired Student t-test. Differences were con-
sidered to be significant at P<0.05.
*
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mal pressor response, except for Ang I which
exhibited a lower maximal contraction, as
shown in Figure 4. When compared on an
equipressor basis from data presented in this
figure (150 mg), Ang II and Ang I were
essentially equipotent while TDP had about
21.0% of the contractile activity of Ang II on
isolated aortic rings.
In intact preparations, the contractions
induced by Ang II, Ang I, and TDP were
completely abolished in the presence of [Sar1-
Ile8]Ang II (50 nM). Addition of captopril
(36 µM) completely blocked the contraction
elicited by both Ang I and TDP, whereas the
response to Ang II was unaffected (Figure
5). Addition of [Sar1-Ile8]Ang II or captopril
to the organ bath did not affect baseline
tension.
After endothelium disruption, confirmed
by the lack of a relaxant effect of Ach, the
vasoconstrictor responses induced by Ang
II, Ang I, and TDP were significantly poten-
tiated. In this condition, the addition of
captopril (36 µM) completely blocked the
contraction elicited by Ang I and TDP,
whereas the response to Ang II was unaf-
fected (Figure 6).
Discussion
The present study shows that the Ang II-
induced vasoconstrictor effect on the iso-
lated rat mesenteric arteries was similar in
the absence and presence of functional en-
dothelium. This observation confirms previ-
ous studies performed on the rabbit aorta
(10), canine carotid artery (15), and bovine
intrapulmonary artery and vein (16). In con-
trast, the Ang II-induced contraction in the
absence of a functional endothelium in rat
aortic rings was approximately two-fold
greater than that observed in intact prepara-
tions. This result supports previous experi-
ments on the rat aorta (13) and bovine coro-
nary artery (16) which showed that destruc-
tion of the endothelium significantly en-
hanced the magnitude of the Ang II-induced
Figure 3 - Changes in perfusion
pressure in the isolated rat mes-
enteric arterial bed induced by
bolus injections of angiotensin II
(Ang II; 19 pmol), angiotensin I
(Ang l; 116 pmol), tetradecapep-
tide (TDP; 568 pmol) renin sub-
strate and acetylcholine (Ach; 11
pmol) in intact and disrupted en-
dothelium preparations in the
absence (upper panel) and in the
presence of 36 µM captopril in
the perfusate (lower panel). Re-
sults are reported as mean ±
SEM and correspond to 8 and 7
observations for the upper and
lower panels, respectively.
*P<0.001 compared to the in-
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Figure 4 - Concentration-re-
sponse curves for angiotensin II
(Ang II; N = 7), angiotensin I (Ang
l; N = 9), and tetradecapeptide
(TDP; N = 5) renin substrate in
intact isolated rat aortic rings.
















Control [Sar1-lle8]Ang II Captopril
* * * **
Figure 5 - Contraction induced
by angiotensin II (Ang II; 5 nM),
angiotensin I (Ang I; 5 nM), and
tetradecapeptide (TDP; 19 nM)
renin substrate in intact isolated
rat aortic rings during a control
period and in the presence of
[Sar1-lle8]Ang II (50 nM) or
captropril (36 µM). Data are re-
ported as mean ± SEM and cor-
respond to 9, 4, and 5 observa-
tions for the control period,
[Sar1-lle8]Ang II, and captopril,
respectively. *P<0.001 com-
pared to the corresponding con-
trol value (paired t-test).
*
*
* * Ang I TDP
Ach
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vasoconstrictor response. The inhibitory ef-
fect of the endothelium on the contraction
induced by Ang II has been attributed to the
release of relaxing factors such as nitric ox-
ide (13,16-18).
Endothelium disruption did not prevent
the local conversion of Ang I or TDP (a
synthetic renin substrate) to Ang II since the
vasoconstrictor effects of both peptides were
unaffected or even potentiated by the perfu-
sion of a detergent or by mechanical disrup-
tion of the endothelium in both mesenteric
arteries and aortic rings. The demonstration
that the Ang II receptor antagonist blocked
the vasoconstrictor effect of Ang II, Ang I,
and TDP in intact and disrupted endotheli-
um vessels strongly suggests that the actions
of both Ang I and TDP were preceded by
their conversion to Ang II in isolated rat
mesenteric arteries and aortic rings. These
findings are in agreement with previous stud-
ies performed on the rat (13) and rabbit aorta
(10).
Ang I is converted to Ang II essentially
by ACE since captopril significantly reduced
the pressor response induced by Ang I in rat
mesenteric arteries and completely blocked
the contraction in aortic rings in prepara-
tions with or without functional endotheli-
um. This finding indicates that a substantial
ACE activity is present in extra-endothelial
layers of the vascular wall, and does not
support previous data indicating that ACE is
mainly localized in the vascular endotheli-
um (8,19). However, our data are in agree-
ment with the results of other pharmacologi-
cal and biochemical studies. In different ves-
sels such as rabbit aorta (10), and rat femoral
(12) and caudal arteries (11), the absence of
endothelium does not alter the functional
response to Ang I. ACE activity, determined
by using a synthetic substrate, was only par-
tially reduced in aortic segments (20) and
was found to be high in perfused mesenteric
arterial bed after endothelium removal (14).
In both cases this activity was sensitive to
blockade by captopril. ACE activity was
also found in rat aortic vascular smooth
muscle cells (21), rat aorta adventitia (22),
and vasa vasorum of the adventitia of large
blood vessels (23). Furthermore, ACE activ-
ity and expression were detected in the me-
dia and the adventitia of the rat aorta (24,25).
Ang II formation from TDP in aortic
rings with or without functional endotheli-
um was found to be a two-step pathway
formation through renin-like enzymes and
ACE since captopril completely blocked the
vasoconstrictor response elicited by TDP.
On the other hand, Ang II formation from
TDP in mesenteric arteries does not involve
the classic renin/ACE pathway since captopril
did not affect the pressor response induced
by TDP in these vessels. These findings
confirm a previous study from our labora-
tory (6) showing that the enhanced responses
to TDP observed in arteries isolated from
one-kidney, one clip hypertensive rats were
not affected by ACE inhibition. Also, the
present results are consistent with those re-
ported for the isolated rat kidney (26) and
isolated rat caudal artery (5), where the en-
hancement of noradrenergic transmission
produced by TDP was unaffected by ACE
inhibition. Furthermore, the contractile ef-
fect of TDP on rat femoral (27) resistance
vessels and on the isolated rat hindlimb (28)
was reported to be insensitive to ACE inhibi-
tion. The failure of an ACE inhibitor to block
the response elicited by TDP strongly sug-
Figure 6 - Contraction induced
by angiotensin II (Ang II; 5 nM),
angiotensin I (Ang l; 5 nM), and
tetradecapeptide (TDP; 19 nM)
renin substrate in intact and dis-
rupted endothelium preparations
of aortic rings in the absence and
in the presence of captopril (36
µM). Data are reported as mean
± SEM and correspond to 5 ob-
servations. *P<0.05 compared
to the intact endothelium value;
**P<0.001 compared to the dis-
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gests that Ang II generation by a non-ACE
pathway may play an important role in the
rat resistance vessels.
Several non-renin enzymes capable of
generating Ang II from angiotensinogen or
Ang I have been described (7,29). In addi-
tion, isolated rat mesenteric bed perfusate,
obtained by recirculating the perfusion solu-
tion, contains a serine protease capable of
releasing Ang II directly from both Ang I and
TDP into the perfusion medium, as moni-
tored by reverse-phase chromatography (30).
In a recent study from our laboratory (31),
we have shown that subpressor doses of Ang
I that potentiate the sympathetic nerve stim-
ulation-induced vasoconstriction in the iso-
lated rat mesenteric bed were not blocked by
captopril. This finding indicated that low
(subpressor) concentrations of Ang I are con-
verted to Ang II mainly by an ACE-inde-
pendent mechanism, while in the present
study, where high (pressor) concentrations
were used, the conversion of Ang I to Ang II
was mainly due to the action of ACE. The
physiological significance of this alternative
pathway of Ang II generation is not clear,
since we do not know whether the TDP renin
substrate behaves like the true renin sub-
strate, angiotensinogen. Nevertheless, the
increase in blood pressure induced by intra-
venous administration of TDP to conscious
rats was not blocked by ACE inhibitor or
pepstatin treatment (6).
The present findings indicate that the
endothelium may not be essential for Ang II
formation in rat mesenteric arteries and aorta,
although it may modulate the response to
Ang II. Although Ang II formation from Ang
I is essentially dependent on ACE in both
vessels, our results indicate the existence of
an alternative pathway in Ang II generation
from TDP in resistance but not in large ves-
sels during ACE inhibition. Whether the con-
tribution of this putative pathway plays a
role in Ang II generation under normal or
pathological condition and during chronic
ACE inhibition remains to be determined.
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